Maureen M Leonard1, Jocelyn A Silvester2, Daniel Leffler3, Alessio Fasano1, Ciarán P Kelly4, Suzanne K Lewis5, Jeffrey D Goldsmith6, Elliot Greenblatt7, William W Kwok8, William J McAuliffe9, Kevin Galinsky9, Jenifer Siegelman9, I-Ting Chow8, John A Wagner9, Anna Sapone9, Glennda Smithson10. 1. Center for Celiac Research and Treatment, Massachusetts General Hospital, Boston, Massachusetts; Celiac Disease Research Program, Harvard Medical School, Boston, Massachusetts. 2. Celiac Disease Research Program, Harvard Medical School, Boston, Massachusetts; Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts; Celiac Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 3. Celiac Disease Research Program, Harvard Medical School, Boston, Massachusetts; Takeda Pharmaceuticals Inc Co, Cambridge, Massachusetts. 4. Celiac Disease Research Program, Harvard Medical School, Boston, Massachusetts; Celiac Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 5. Department of Medicine, Columbia University Medical Center, New York, New York. 6. Celiac Disease Research Program, Harvard Medical School, Boston, Massachusetts; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts. 7. Invicro, A Konica Minolta Company, Boston, Massachusetts. 8. Benaroya Research Institute at Virginia Mason, Seattle, Washington. 9. Takeda Pharmaceuticals Inc Co, Cambridge, Massachusetts. 10. Takeda Pharmaceuticals Inc Co, Cambridge, Massachusetts. Electronic address: glennda.smithson@takeda.com.
Abstract
BACKGROUND & AIMS: Gluten challenge is used to diagnose celiac disease (CeD) and for clinical research. Sustained gluten exposure reliably induces histologic changes but is burdensome. We investigated the relative abilities of multiple biomarkers to assess disease activity induced by 2 gluten doses, and aimed to identify biomarkers to supplement or replace histology. METHODS: In this randomized, double-blind, 2-dose gluten-challenge trial conducted in 2 US centers (Boston, MA), 14 adults with biopsy-proven CeD were randomized to 3 g or 10 g gluten/d for 14 days. The study was powered to detect changes in villous height to crypt depth, and stopped at planned interim analysis on reaching this end point. Additional end points included gluten-specific cluster of differentiation (CD)4 T-cell analysis with HLA-DQ2-gluten tetramers and enzyme-linked immune absorbent spot, gut-homing CD8 T cells, interleukin-2, symptoms, video capsule endoscopy, intraepithelial leukocytes, and tissue multiplex immunofluorescence. RESULTS: All assessments showed changes with gluten challenge. However, time to maximal change, change magnitude, and gluten dose-response relationship varied. Villous height to crypt depth, video capsule endoscopy enteropathy score, enzyme-linked immune absorbent spot, gut-homing CD8 T cells, intraepithelial leukocyte counts, and HLA-DQ2-restricted gluten-specific CD4 T cells showed significant changes from baseline at 10 g gluten only; symptoms were significant at 3 g. Symptoms and plasma interleukin-2 levels increased significantly or near significantly at both doses. Interleukin-2 appeared to be the earliest, most sensitive marker of acute gluten exposure. CONCLUSIONS: Modern biomarkers are sensitive and responsive to gluten exposure, potentially allowing less invasive, lower-dose, shorter-duration gluten ingestion. This work provides a preliminary framework for rational design of gluten challenge for CeD research. ClinicalTrials.gov number, NCT03409796.
BACKGROUND & AIMS: Gluten challenge is used to diagnose celiac disease (CeD) and for clinical research. Sustained gluten exposure reliably induces histologic changes but is burdensome. We investigated the relative abilities of multiple biomarkers to assess disease activity induced by 2 gluten doses, and aimed to identify biomarkers to supplement or replace histology. METHODS: In this randomized, double-blind, 2-dose gluten-challenge trial conducted in 2 US centers (Boston, MA), 14 adults with biopsy-proven CeD were randomized to 3 g or 10 g gluten/d for 14 days. The study was powered to detect changes in villous height to crypt depth, and stopped at planned interim analysis on reaching this end point. Additional end points included gluten-specific cluster of differentiation (CD)4 T-cell analysis with HLA-DQ2-gluten tetramers and enzyme-linked immune absorbent spot, gut-homing CD8 T cells, interleukin-2, symptoms, video capsule endoscopy, intraepithelial leukocytes, and tissue multiplex immunofluorescence. RESULTS: All assessments showed changes with gluten challenge. However, time to maximal change, change magnitude, and gluten dose-response relationship varied. Villous height to crypt depth, video capsule endoscopy enteropathy score, enzyme-linked immune absorbent spot, gut-homing CD8 T cells, intraepithelial leukocyte counts, and HLA-DQ2-restricted gluten-specific CD4 T cells showed significant changes from baseline at 10 g gluten only; symptoms were significant at 3 g. Symptoms and plasma interleukin-2 levels increased significantly or near significantly at both doses. Interleukin-2 appeared to be the earliest, most sensitive marker of acute gluten exposure. CONCLUSIONS: Modern biomarkers are sensitive and responsive to gluten exposure, potentially allowing less invasive, lower-dose, shorter-duration gluten ingestion. This work provides a preliminary framework for rational design of gluten challenge for CeD research. ClinicalTrials.gov number, NCT03409796.
Authors: Daniel A Leffler; Sarah Acaster; Katy Gallop; Melinda Dennis; Ciarán P Kelly; Daniel C Adelman Journal: Value Health Date: 2017-02-14 Impact factor: 5.725
Authors: Louise F Risnes; Asbjørn Christophersen; Shiva Dahal-Koirala; Ralf S Neumann; Geir K Sandve; Vikas K Sarna; Knut Ea Lundin; Shuo-Wang Qiao; Ludvig M Sollid Journal: J Clin Invest Date: 2018-05-14 Impact factor: 14.808
Authors: Prashant Singh; Ananya Arora; Tor A Strand; Daniel A Leffler; Carlo Catassi; Peter H Green; Ciaran P Kelly; Vineet Ahuja; Govind K Makharia Journal: Clin Gastroenterol Hepatol Date: 2018-03-16 Impact factor: 11.382
Authors: Michael Bodd; Melinda Ráki; Elin Bergseng; Jørgen Jahnsen; Knut E A Lundin; Ludvig M Sollid Journal: Eur J Immunol Date: 2013-07-15 Impact factor: 5.532
Authors: Marlou P M Adriaanse; Daniel A Leffler; Ciaran P Kelly; Detlef Schuppan; Robert M Najarian; Jeffrey D Goldsmith; Wim A Buurman; Anita C E Vreugdenhil Journal: Am J Gastroenterol Date: 2016-05-17 Impact factor: 10.864
Authors: Jason A Tye-Din; Gry I Skodje; Vikas K Sarna; John L Dzuris; Amy K Russell; Gautam Goel; Suyue Wang; Kaela E Goldstein; Leslie J Williams; Ludvig M Sollid; Knut Ea Lundin; Robert P Anderson Journal: United European Gastroenterol J Date: 2019-09-03 Impact factor: 4.623
Authors: Gautam Goel; Jason A Tye-Din; Shuo-Wang Qiao; Amy K Russell; Toufic Mayassi; Cezary Ciszewski; Vikas K Sarna; Suyue Wang; Kaela E Goldstein; John L Dzuris; Leslie J Williams; Ramnik J Xavier; Knut E A Lundin; Bana Jabri; Ludvig M Sollid; Robert P Anderson Journal: Sci Adv Date: 2019-08-07 Impact factor: 14.136
Authors: Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai Journal: Nat Rev Gastroenterol Hepatol Date: 2022-01-03 Impact factor: 46.802
Authors: Jordy P W Burger; Ellen G van Lochem; Elisabeth A Roovers; Joost P H Drenth; Peter J Wahab Journal: Nutrients Date: 2022-04-23 Impact factor: 6.706
Authors: Ciarán P Kelly; Joseph A Murray; Daniel A Leffler; Daniel R Getts; Adam C Bledsoe; Glennda Smithson; M Roy First; Amy Morris; Michael Boyne; Adam Elhofy; Tsung-Teh Wu; Joseph R Podojil; Stephen D Miller Journal: Gastroenterology Date: 2021-03-17 Impact factor: 33.883
Authors: Anupam Rej; Michael D E Potter; Nicholas J Talley; Ayesha Shah; Gerald Holtmann; David Surendran Sanders Journal: Am J Gastroenterol Date: 2022-04-08 Impact factor: 12.045
Authors: Sandip K Wagh; Karen M Lammers; Manohar V Padul; Alfonso Rodriguez-Herrera; Veronica I Dodero Journal: Int J Mol Sci Date: 2022-10-04 Impact factor: 6.208
Authors: M Ines Pinto-Sanchez; Jocelyn A Silvester; Benjamin Lebwohl; Daniel A Leffler; Robert P Anderson; Amelie Therrien; Ciaran P Kelly; Elena F Verdu Journal: Nat Rev Gastroenterol Hepatol Date: 2021-09-15 Impact factor: 46.802